Analysts Lower Price Targets for Neurocrine, NXP Semiconductors, NBT Bancorp

Neurocrine Biosciences (NBIX) has seen its stock performance decline over the past year, losing over 23%, and continues to face volatility, although analysts remain largely optimistic about its future prospects. Multiple research firms, including Canaccord Genuity, HC Wainwright, and UBS Group, have recently reduced their price targets for NBIX but have maintained buy ratings, with the consensus target price now averaging around $160.90. Analysts predict strong earnings growth for NBIX, with EPS expected to grow significantly both this year and next. Institutional investors hold a minority stake in the company, which maintains a moderate buy consensus from analysts. Despite missing recent earnings expectations, Neurocrine Biosciences continues to receive positive outlooks due to anticipated long-term growth. The company has also initiated a share repurchase program, reflecting management's confidence in its future performance.